Seeing the need to protect and regenerate tissue
Learn more about us
Kerecis was founded to develop sustainable, science-driven treatments to address global health issues.
The company is pioneering the use of fish skin and fatty acids in the cellular-therapy and regenerative-tissue markets. The products from the company’s patented technologies protect the body’s own tissues, provide an infection barrier, and enable the body to regenerate tissues.
These products, which are based on intact fish skin and fish- and plant-derived fatty acids, are currently being used to protect and regenerate tissue in diabetic and trauma wounds, and to control infections.
The company’s mission is to extend human life by supporting the body’s own ability to protect and regenerate tissues. Its vision is to become world leader in regenerating damaged human tissues by sustainably harnessing nature’s own remedies.
Operations & Structure
Kerecis’s operational headquarters are located in Arlington, Virginia, near Washington D.C. Research & Development is based in Reykjavik Iceland with European and Asian sales run from the Company’s office in Zurich, Switzerland. The Kerecis products are manufactured in its own manufacturing facility in Isafjordur, Iceland.
Kerecis sells its product through a mixture of direct sales in the U.S., and employs agents and distributors worldwide. The products are sold to hospitals, healthcare facilities, physicians and consumers.
The company is privately held by Icelandic, American, British and French shareholders. About one third of the shareholders are the original founders of the business. Private investors and family funds hold the remaining shares. The five largest shareholders are:
- Emerson Collective LLC
- Omega ehf (affiliated with Novator Partners LLP)
- CuraeLab SARL
- BBL 34 ehf
- FnF ehf
The most recent shareholder, Laurene Powell Jobs invested in the company through Emerson Collective LLC, in 2019. President Olafur Ragnar Grimsson, the former President of Iceland represents Emerson Collective on the board of Kerecis.
Kerecis products utilize multiple patented fatty-acid technologies to protect and regenerate tissue across two core technologies: Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxide. Kerecis products categorize as medical devices and go through a rigorous process to be approved and commercialized in countries around the world. The Kerecis technology is patented in the United States and in more than 40 other countries.
Kerecis participates in several projects funded by governments around the world including the United States (Department of Defense or the DoD) and the EU. The company is committed to developing better remedies for injured American servicemen and women.
Kerecis is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical trials. Ideal potential technology licensees will have the ability to launch these proprietary devices in markets around the world.
The Kerecis Omega3 Fish Skin technology was invented by the company’s founder and CEO, Fertram Sigurjonsson. The company started commercial operations in 2013 and established its U.S. headquarters in 2016.
In 2019, the company acquired the Swiss life-science company Phytoceuticals AG, which has since changed its name to Kerecis AG. This acquisition brought with it the Omega3 Viruxide technology.
Kerecis provides medical assistance to physicians and surgeons performing procedures and medical consultancy.